INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
INmune Bio (NASDAQ:INMB) reported Q1 2024 GAAP EPS of $(0.61), missing the $(0.54) estimate, and sales of $14K, missing the $30K estimate. This represents a significant decrease in performance compared to the same period last year.
May 09, 2024 | 8:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
INmune Bio reported a larger than expected loss per share and a significant miss in sales for Q1 2024, indicating a downturn in its financial performance.
The reported earnings miss and significant sales shortfall compared to analyst expectations suggest a negative short-term impact on INmune Bio's stock price. The comparison to last year's performance further emphasizes the company's current financial struggles, likely leading to decreased investor confidence.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100